ASST-01 — Bottom-Fishing the New Bitcoin Dark Horse. What Happens When You Stack Politics + Capital + Biotech?

Date: 2025-11-10 Ticker: ASST (Strive Asset Management) Source: https://www.youtube.com/watch?v=tDIfuJdHE5c

Summary

• ASST is a Bitcoin treasury company that's structurally very different from MSTR. Speaker moved his entire MSTR position into ASST. Stock at $1.50, with three prior peaks at $10-13 in the past 6 months — implies ~8x upside if it returns to peak. Market cap ~$1.04B, P/B 1.2, BTC holdings worth ~$1.2B (so trading slightly below NAV — safe entry zone).
• The model: Instead of issuing convertible debt to fund BTC purchases (MSTR's playbook, which carries blowup risk if BTC drops 80%+), ASST acquires struggling biotech companies that hold Bitcoin on their treasury. Strips out the BTC, spins off the biotech R&D. Like buying foreclosure homes — same asset, but at a discount. Funds itself via PIPE (private placement) and ATM (at-the-market offerings) — no convertible debt = no leverage blowup risk.
• Founder is Vivek Ramaswamy (born 1985, Indian-American). Harvard biology 2007 → Yale law 2013 → founded Roivant Sciences (biotech holding co.) → 2024 Republican presidential primary (came 4th) → ran DOGE briefly with Musk → planning Ohio governor 2026 run. Holds 20.7% directly + controls majority voting power via Class B shares + recently bought 1.42M shares ($1.25M) personally. Initial investors include Peter Thiel, JD Vance, Bill Ackman ($20M total). Politics + biotech network + capital all converge here.
• Trading plan: Two drivers — (1) ASST's own acquisition catalysts (each new biotech-Bitcoin acquisition repricies the equity), (2) crypto sector rebound (October liquidity crunch caused gold/silver/crypto sell-off; that leverage is now off). Volatility will be massive. Strategy: sell at least half on the next fast spike — these companies always do an ATM raise after a pop, which crashes the price for the next leg.

Translation

There's a Bitcoin treasury company I want to talk about today. It's not like MSTR — they don't use leverage. I think long-term it could grow much faster than MSTR, and right now the stock is at a low. It caught my attention recently, and I moved my entire MSTR position into this company.

Hello everyone, this is X. All my videos are personal investment notes and biased reflections. Not investment advice. Manage your own risk. Don't invest in things you don't understand. Don't blindly chase highs.

Today: another piece in the wealth puzzle — ASST, company name Strive.

Price action

It's Monday Nov 10, 2025. Last week US markets had a big pullback (late October to early November). Pre-market today, crypto-sphere is rallying hard.

Stock is at $1.50. Looking at the chart — three prior peaks all around $12, with the high at $13 and the lower one at $10. That's roughly 8x upside to those peaks from here.

Why this kind of stock interests me: three peaks in close succession in the past 6 months. Whatever the story / expectation, it's been able to reach those levels in short order. We're at a trough now. I'm betting on whether the next peak comes soon.

Timeline: first peak was May 6, 2025. Before that, the stock was flat — the company isn't long-listed (registry says 2023, but I think they came in via a reverse merger). Since May they've been making moves roughly every 2 months.

• Market cap: ~$1.04B (other sources show $1.2B — both data points basically consistent)
• P/B: 1.2 (very low — close to the cash/BTC value, no premium)
• Headcount: 51 (small, but enough for a treasury company)
• Cash on hand: low, but this isn't a cash-strapped story — they don't fund BTC purchases by spending cash directly

Business model — the key differentiator vs. MSTR

Two distinguishing features:

1. They acquire BTC by acquiring companies, not by buying BTC outright.

Specifically: they acquire small/struggling biotech companies that happen to hold Bitcoin on their balance sheet (as a treasury reserve strategy). Those biotechs accumulated BTC at low prices earlier. Strive buys the biotech, marks the BTC to current market value, separates the biotech R&D operations (sells / spins out / lets the original team run it), and keeps the Bitcoin.

It's like buying a foreclosure home from a bank — same asset, but at a discount. The biotech sellers don't want their BTC, they want cash. Strive gets the BTC at favorable terms.

This requires: - Industry network — knowing which biotechs hold BTC and might sell - Insider access — early conversations before deals become public

2. They don't use convertible debt — no leverage.

MSTR's primary capital tool is convertible debt. Convertibles aren't the most dangerous form of leverage, but they carry real risk: if your BTC value crashes hard enough, the convertible obligation can liquidate you. MSTR's safety margin is around the 30%+ range against asset value; they've been talking about lowering that to ~20%, which would mean if BTC drops ~80%, MSTR could blow up.

Strive doesn't issue convertible debt at all. Instead they use: - PIPE (private placement) — investors put up cash, they get equity proportional, share future profits - ATM (at-the-market) — raise capital from public market shareholders

Same model as BMNR (Tom Lee's ETH treasury company) and similar plays — money in, equity out, BTC purchased, no leverage. Practically zero leverage blowup risk.

The downside vs. MSTR's approach: if you can pull off the convertible bond strategy without blowing up, the leverage juices returns. But Strive's argument is: structural acquisition discounts > leverage juice. Buying BTC by acquiring biotechs at a discount is their alpha.

Team

Very new team: - CEO Matthew Cole — less than 1 year tenure - Management team avg: less than 1 year - Board avg: ~0.2 years - CEO holds only 1.65% / second exec Benjamin Pham ~0.6%

Normally the brand-new team would worry me, but every company starts somewhere — even an experienced doctor saw their first patient at age 25. The thing to look at is the substance.

The substance here is the founder/biggest shareholder behind the new team — that's where the depth is.

Ownership

• Retail (general public): ~40%
• Insiders: 31.8% (very high, very concentrated — voting bloc not yet diluted)
• Institutions: 23.1%
• Hedge funds: ~5%
• Recent insider activity: CEO and execs bought stock in September 2025 (purchases, not sales). Three investors + one company added ~$900K. Reported portion is likely smaller than actual.

Top holders: - Vivek Ramaswamy: 20.7% (founder) - Lawrence: 5.93% - Anson Group: 5.12% - Citadel Advisors: 5% - Two more positions ~4.5-4.9%

Citadel showing up as a 5% holder is notable — that's serious institutional capital.

Short interest: nearly zero. The recent liquidity crunch already washed out leverage and high-risk positions; not much shorting going on now.

The founder — Vivek Ramaswamy

Born 1985 (40 years old). Indian-American, US-born to Indian immigrant parents (Tamil Brahmin caste).

Education: - Harvard, biology, 2007 - Yale Law, 2013 — and net worth was already $15M before he graduated law school

Companies: - Roivant Sciences (biotech) — founded 2014. "ROI" = return on investment, that's the name. Multi-company biotech holding structure. - One of his subsidiaries (Axovant) crashed 75% in a single day in 2017 after a clinical trial failure. Significant losses for institutional shareholders. But because Roivant held its stake at the holdco level, the parent was buffered. Axovant itself was dissolved in 2023. - 2017 — partnered with CITIC Group (China state-owned) and CITIC Private Equity. - 2017 — SoftBank invested $1.1B into Roivant. Sold 5 portfolio companies' equity to Sumitomo Pharma — Vivek personally pocketed $175M in capital gains from this transaction.

So before he turned 35, this guy had: - Built a multi-company biotech portfolio - Cut deals with CITIC, SoftBank, Sumitomo - Successfully exited large positions

He'd worked at a hedge fund earlier — co-managed the biotech investment portfolio as a partner. So the biotech industry network is real, and that network is exactly what Strive exploits when sourcing BTC-holding biotechs to acquire.

Politics: - Politically neutral until 2020 - Started supporting Trump in the 2020 election - Anti-woke / anti-DEI / anti-affirmative-action / anti-CRT — fully aligned with the right-wing of the Republican Party - 2024 Republican primary — placed 4th, then dropped out and threw full support to Trump (had said he'd pardon Trump if elected, even before becoming aggressive in Trump support) - Met JD Vance (now VP) at Yale Law — they're both from Ohio - Ran DOGE briefly with Musk — even when DOGE blew up between Trump and Musk, Vivek avoided getting caught in the conflict; Musk has continued to publicly support him - Announced 2026 Ohio governor run — Trump endorses, born in Ohio, very high probability of winning

Strive's initial $20M came from: - Peter Thiel - JD Vance - Bill Ackman - + political capital network

Founded with Anson Frederick in 2022.

Recent SEC 13D filing: he bought 15,000+ preferred shares for $1.25M in November 2025 (just days before this video). Holds 1.42M+ Class B shares directly + indirectly, controlling majority voting power. Reverse merger plus a $7.5M PIPE (might be $750M if scale unit error, but more likely $7.5M). All related entities combined: >50% voting power.

This founder is firmly in control of this company. Heavily personally invested.

His wife is an ENT/surgeon, met at Yale, several children.

Why I'm in this position

When you connect Vivek's dots — biotech network + biotech holdco operating experience + capital relationships (Thiel, Vance, Ackman, Citadel) + political access (Trump, VP, governor candidacy) + zero-leverage structure — this is what Steve Jobs called connecting the dots. The result is a vehicle uniquely positioned to acquire BTC at structural discounts.

That's why I moved out of MSTR into ASST.

What I'm watching for

Catalyst: the next biotech acquisition with embedded BTC. Every time they announce one, the stock should reprice up.

Current valuation safety: ASST's BTC holdings are worth about $1.2B; market cap is $1.04B. Trading at slight discount to NAV — relatively safe entry.

I built my position last week and now I'm just waiting for news. New playbook though, so I'm reminding myself: don't only see the thief eating meat — watch out for the thief getting beaten (贼吃肉，不看到贼挨打 — i.e., don't focus only on upside, the downside is real).

When the stock spikes, they will almost certainly do an ATM offering to raise capital for the next BTC acquisition — and that always crashes the price afterward. So volatility will be huge. This position is part real conviction in fundamentals, part short-term speculation.

Trading plan: if it spikes hard and fast, I'll sell at least half. Specifically — if it runs sharply for 1-2 days, it's not sustainable, because the news has been priced in and they'll need to raise to fund the next acquisition.

Macro setup

A note on context like BMNR. We're not in the early-stage moonshot regime anymore — that's when one news item sent these things straight to the moon. Now they're in the issue-then-pull, issue-then-pull cycle, which means swings are slower. Until they reach a critical reserve size, the multi-bagger-premium re-rating doesn't really show up — the market keeps reverting them back to NAV (BTC or ETH value).

That said, October's gold/silver/crypto sell-off was a liquidity event — derivatives and leverage being unwound, cash needed elsewhere. That leverage is now off, which means new capital is rotating back in. Crypto has been consolidating sideways for a long stretch. If crypto rallies from here, ASST's valuation rallies with the underlying — that's a second tailwind on top of the acquisition story.

So two drivers: 1. Their own deal flow (each acquisition = catalyst) 2. Underlying crypto rebound (sector beta on a discounted base)

That's the logic.

OK, that's the share for today. Thank you. Wishing everyone financial freedom soon. See you next time. Bye-bye.